Rinvoq®(upadacitinib) – New indication
April 29, 2022 - AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Download PDF
